AGPS
Alkyldihydroxyacetonephosphate synthase, peroxisomal
Also known as: ADAP-S, ADAS, ADAS_HUMAN, ADHAPS, ADPS, ALDHPSY
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O00116
- Gene
- AGPS
- Ensembl
- ENSG00000018510
- Chromosome
- 2
- Canonical length
- 658 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Peroxisomes
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene is a member of the FAD-binding oxidoreductase/transferase type 4 family. It encodes a protein that catalyzes the second step of ether lipid biosynthesis in which acyl-dihydroxyacetonephosphate (DHAP) is converted to alkyl-DHAP by the addition of a long chain alcohol and the removal of a long-chain acid anion. The protein is localized to the inner aspect of the peroxisomal membrane and requires FAD as a cofactor. Mutations in this gene have been associated with rhizomelic chondrodysplasia punctata, type 3 and Zellweger syndrome. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
658 residues, UniProt reviewed canonical sequence.
>O00116|AGPS
1 MAEAAAAAGG TGLGAGASYG SAADRDRDPD PDRAGRRLRV LSGHLLGRPR EALSTNECKA
61 RRAASAATAA PTATPAAQES GTIPKKRQEV MKWNGWGYND SKFIFNKKGQ IELTGKRYPL
121 SGMGLPTFKE WIQNTLGVNV EHKTTSKASL NPSDTPPSVV NEDFLHDLKE TNISYSQEAD
181 DRVFRAHGHC LHEIFLLREG MFERIPDIVL WPTCHDDVVK IVNLACKYNL CIIPIGGGTS
241 VSYGLMCPAD ETRTIISLDT SQMNRILWVD ENNLTAHVEA GITGQELERQ LKESGYCTGH
301 EPDSLEFSTV GGWVSTRASG MKKNIYGNIE DLVVHIKMVT PRGIIEKSCQ GPRMSTGPDI
361 HHFIMGSEGT LGVITEATIK IRPVPEYQKY GSVAFPNFEQ GVACLREIAK QRCAPASIRL
421 MDNKQFQFGH ALKPQVSSIF TSFLDGLKKF YITKFKGFDP NQLSVATLLF EGDREKVLQH
481 EKQVYDIAAK FGGLAAGEDN GQRGYLLTYV IAYIRDLALE YYVLGESFET SAPWDRVVDL
541 CRNVKERITR ECKEKGVQFA PFSTCRVTQT YDAGACIYFY FAFNYRGISD PLTVFEQTEA
601 AAREEILANG GSLSHHHGVG KLRKQWLKES ISDVGFGMLK SVKEYVDPNN IFGNRNLLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AGPS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 21 nTPM
Expression across tissuesHPA
Tissue
- rectum: 21 nTPM
- smooth muscle: 20 nTPM
- colon: 19 nTPM
- bone marrow: 19 nTPM
- liver: 18 nTPM
- parathyroid gland: 17 nTPM
Single-cell type
- hematopoietic stem cells: 1,042 nCPM
- neutrophil progenitors: 517 nCPM
- breast lactating cells: 286 nCPM
- thymocytes: 281 nCPM
- early spermatids: 252 nCPM
- late primary spermatocytes: 242 nCPM
Immune cell
- eosinophil: 5.8 nTPM
- T-reg: 4.3 nTPM
- intermediate monocyte: 4.1 nTPM
- myeloid DC: 3.6 nTPM
- non-classical monocyte: 3.6 nTPM
- classical monocyte: 3.3 nTPM
Brain region
- white matter: 31 nTPM
- medulla oblongata: 25 nTPM
- spinal cord: 22 nTPM
- pons: 21 nTPM
- cerebellum: 20 nTPM
- midbrain: 20 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AGPS.
Disease | AllUniProt
Conditions AGPS is implicated in, by any mechanism.
- Rhizomelic chondrodysplasia punctata 3 (RCDP3) MIM:600121
Disease | GeneticClinVar
30 pathogenic / likely-pathogenic of 815 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Rhizomelic chondrodysplasia punctata type 3
- Rhizomelic chondrodysplasia punctata
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.12
- gnomAD pLI
- 1
- gnomAD missense Z
- 3.23
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- FAD binding
- alkylglycerone-phosphate synthase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- FAD-binding oxidoreductase/transferase, type 4, C-terminal
- FAD linked oxidase, N-terminal
- FAD-linked oxidase-like, C-terminal
- FAD-binding domain, PCMH-type
- FAD-binding, type PCMH, subdomain 1
- FAD-binding, type PCMH, subdomain 2
- Vanillyl-alcohol oxidase, C-terminal subdomain 2
- FAD-binding, type PCMH-like superfamily
- FAD binding domain
- FAD linked oxidases, C-terminal domain
- Alkyldihydroxyacetonephosphate synthase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of AGPS in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AGPS as an antibody target. Whether an autoantibody or antibody against AGPS could matter depends on whether native AGPS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AGPS is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AGPS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...